CEO Thomas C. Chen purchased $130k worth of NTHI stock at $3.85, marking the largest insider purchase in the company's history. This bullish signal comes as the stock has surged 42.61% over the last 30 days, potentially signaling confidence in recent clinical milestones.
Price context
NTHI is up 42.61% over the last 30 days and 13.23% over the last 5 days, trading at $4.92, which is 59.22% above its 52-week low of $3.09 but still down 62.12% from its 52-week high of $12.99.
Catalysts to watch
- •Upcoming investor conference call on Wednesday, August 12, 2026, to discuss topline Phase 2a results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma.
- •FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition received on July 15, 2026.
- •UAE IND Approval for NEO100 received on June 23, 2026, expanding global development ahead of anticipated Phase 2 data milestones.
Risks
- •The stock is currently down 9.06% over the last 90 days, indicating recent volatility despite the 30-day rally.
- •The company has a short interest of 5.70% of the float, which could lead to short-covering driven volatility if the stock continues to rise.
AI-generated context from public data. Not investment advice. Verify before trading.